Waters Corporation Acquires Calorimetry Sciences Corporation

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) announced today the acquisition of Calorimetry Sciences Corporation, “CSC”, (Linden, UT), a manufacturer of high-performance calorimeters. The CSC business, with annual sales of approximately $4 million, will be added to Waters’ TA Instruments Division (New Castle, DE) and the transaction is expected to be neutral to Waters 2007 earnings.

“The technologies and products from CSC will complement our recently introduced TAMTM microcalorimeter product line and will further strengthen TA Instruments’ industry-leading position in thermal analysis while increasing our exposure to the growing adoption of microcalorimetry in life science research and drug development.”

Commenting on the acquisition, Terry Kelly, President of TA Instruments said, “The technologies and products from CSC will complement our recently introduced TAM^TM microcalorimeter product line and will further strengthen TA Instruments’ industry-leading position in thermal analysis while increasing our exposure to the growing adoption of microcalorimetry in life science research and drug development."

Waters Corporation holds worldwide leading positions in three complementary analytical technologies - liquid chromatography, mass spectrometry, and thermal analysis. These markets account for approximately $5.0 billion of the estimated $20 - $25 billion analytical instrumentation market.

Calorimetry Sciences Corporation operated as a privately held company in Linden, Utah. Key products developed and offered by CSC include the Nano-ITC^TM, an isothermal titration calorimeter designed to measure protein-ligand binding, and the Nano-DSC^TM, an ultra-sensitive scanning calorimeter used for applications such as measuring the stability of proteins and other macro-molecules in dilute solutions.

Certain statements contained herein are forward looking. Many factors could cause actual results to differ from these statements, including delays in product introductions, loss of market share through competition, introduction of competing products by other companies, pressures on prices from competitors and/or customers, regulatory obstacles to new product introductions, lack of acceptance of new products, changes in the healthcare market and the pharmaceutical industry, changes in distribution of the Company’s products, and foreign exchange fluctuations. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s annual report on Form 10K for the year ended December 31, 2006 and quarterly report on Form 10Q for the period ended June 30, 2007, as filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this release.